Drug intelligence / Profile preview

LIB125

Development stage: Preclinical
Lead developer: Libera Bio
Modality: Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

LIB125 is a preclinical-stage monoclonal antibody developed by LiberaBio that specifically targets the KRAS G12V mutation. A significant challenge in targeting KRAS with biologics is its intracellular location; LIB125 addresses this by utilizing LiberaBio's proprietary Multifunctional Polymeric Nanoparticles (MPN Technology®). This delivery system enables the monoclonal antibody to cross the cell membrane and reach its target within the cytosol. By binding to the KRAS G12V mutant protein, LIB125 aims to inhibit the downstream signaling pathways that drive tumor growth and progression. The program is currently in the lead generation and proof-of-concept phase.

Other names: LIB125-LiberaBio-KRAS G12V-monoclonal antibodyLIB-125-LiberaBio-KRAS G12V-monoclonal antibodyLIB 125-LiberaBio-KRAS G12V-monoclonal antibodyLiberaBio KRAS G12V antibody

Targets

KRASG12V (KRAS G12V)

Beyond the preview

Go deeper on LIB125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIB125.

Explore the full profile